Title:
PHTHALAZONE DERIVATIVE PRODRUG OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF
Document Type and Number:
WIPO Patent Application WO/2019/144875
Kind Code:
A1
Abstract:
The present invention relates to the technical field of medicinal chemistry, and relates in particular to a phthalazone derivative prodrug or a pharmaceutically acceptable salt thereof, and relates to a pharmaceutical composition thereof and an application thereof in the preparation of an anti-tumor drug. The phthalazone derivative prodrug represented by structural formula (I) provided by the present invention has good in vivo solubility; after being administered into the body, phthalazone molecules are released following metabolization, which greatly improves the in vivo bioavailability of the phthalazone molecules; the phthalazone molecules bind to poly(ADP-ribose) polymerase (PARP) enzymes in the body in an irreversible manner to give rise to a medical effect, and the anti-tumor activity is obvious.
Inventors:
GAO HEYONG (CN)
LIU ZHENDE (CN)
ZHANG WENSHENG (CN)
LIU ZHENDE (CN)
ZHANG WENSHENG (CN)
Application Number:
PCT/CN2019/072779
Publication Date:
August 01, 2019
Filing Date:
January 23, 2019
Export Citation:
Assignee:
SHANGHAI BIOBOND PHARMACEUTICAL CO LTD (CN)
International Classes:
C07D237/32; A61K31/502; A61P35/00
Foreign References:
| CN108383798A | 2018-08-10 | |||
| CN106146557A | 2016-11-23 | |||
| CN1788000A | 2006-06-14 | |||
| CN101801960A | 2010-08-11 |
Attorney, Agent or Firm:
SHANGHAI SHENXIN LAW FIRM (CN)
Download PDF: